A single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib, and bevacizumab for initial treatment of glioblastoma (GBM).
Jennifer Leigh Clarke
No relevant relationships to disclose
Annette M Molinaro
No relevant relationships to disclose
Nicholas A. Butowski
Honoraria - Genentech
Susan Marina Chang
No relevant relationships to disclose
Joanna J Phillips
No relevant relationships to disclose
Bruno M Costa
No relevant relationships to disclose
Joseph F Costello
No relevant relationships to disclose
Jane E Rabbitt
No relevant relationships to disclose
Valerie A Kivett
No relevant relationships to disclose
Ashley A DeSilva
No relevant relationships to disclose
Michael Prados
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Expert Testimony - Genentech (U)